FDA Approves Xeomin for temporary improvement to frown lines between the brows

Merz Aesthetics today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Xeomin (incobotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.